BiotechTube

CT-P13 SC (Infliximab)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Sep 1, 2020 → Jul 11, 2023

NCT ID
NCT04205643

About CT-P13 SC (Infliximab)

CT-P13 SC (Infliximab) is a phase 3 stage product being developed by Celltrion for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04205643. Target conditions include Ulcerative Colitis.

What happened to similar drugs?

15 of 20 similar drugs in Ulcerative Colitis were approved

Approved (15) Terminated (5) Active (5)
✅Azathioprine + PlaceboCelltrionApproved
✅Filgotinib MaleateEisaiApproved
✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved
✅AdalimumabAbbVieApproved
✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved
✅GolimumabMerckApproved
✅GolimumabMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04205643Phase 3Completed
NCT03945019Phase 3Completed

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
40
MirikizumabEli LillyPhase 2
35
Azathioprine + PlaceboCelltrionApproved
35
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
TacrolimusAstellas PharmaPhase 3
40
tacrolimus + PlaceboAstellas PharmaPhase 3
40
Filgotinib MaleateEisaiApproved
50
AJM300 + PlaceboEisaiPhase 3
40
GSK3050002 + PlaceboEisaiPhase 1
29
adalimumab + placeboEisaiPhase 3
40
E6007 + PlaceboEisaiPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 1
29
Arm1 + Arm 2Zydus LifesciencesPhase 2
35
Mirikizumab + MirikizumabEli LillyPhase 3
44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 2
27
Mirikizumab + PlaceboEli LillyPhase 2
35
LY4268989 + PlaceboEli LillyPhase 2
42
Eltrekibart + Mirikizumab + PlaceboEli LillyPhase 2
42